Gordon J Freeman

59PUBLICATIONS
379CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Jun 17, 2026
IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

|Jun 15, 2026
Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.

|May 04, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.

|Apr 08, 2026
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection.

Masao Hashimoto, Tahseen H Nasti, Hyun-Tak Jin

|Mar 26, 2026
Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion.

Christopher B Medina, Ewelina Sobierajska, Minghao Gong

Pageof 10

Frequent Collaborators

12 joint publications

Arlene H Sharpe

7 joint publications

Wenyi Wei

6 joint publications

Jinfang Zhang

6 joint publications

Catherine J Wu